QTTB
Q32 BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The core bull case is that Q32 has narrowed the story to bempikibart, completed SIGNAL-AA Part B enrollment, and still guides to a mid-2026 topline readout while runway extends into late 2027 if management assumptions hold [#10-K-2026-03-10] [#PR-2026-03-10].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.2.
What can break
ATM usage could create incremental dilution and pressure sentiment.
Momentum
99
Value
44
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $10.00 · Bear $2.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $38.75
Why
Momentum99 · Δ7d +0.2
Value44 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.6
Value
44
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 99.1 / Value 44.2 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$356.17M
Beta
0.17
Shares Out
23.68M
P/E (TTM) · Derived
6.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.96
Rev YoY
-100.0%
EPS YoY
-40.3%
Gross Margin
+99.3%
Op Margin
-
Net Debt
-$32.95M
Current Ratio
5.33
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology